The recently disclosed FTO inhibitors, CS1 and CS2, exhibit impressive effectiveness in suppressing the proliferation of AML cells in vitro and in PDX models in vivo by targeting FTO’s demethylation activity [109]. Here, FTO is linked to acute myeloid leukemia.